Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.16)
# 425
Out of 5,173 analysts
521
Total ratings
46.61%
Success rate
15.01%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NERV Minerva Neurosciences | Maintains: Neutral | $4 → $7 | $6.55 | +6.87% | 16 | Mar 12, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $53 → $74 | $54.42 | +35.98% | 6 | Mar 10, 2026 | |
| BHVN Biohaven | Maintains: Neutral | $11 → $10 | $8.74 | +14.42% | 18 | Mar 4, 2026 | |
| TBPH Theravance Biopharma | Maintains: Buy | $27 → $15 | $14.75 | +1.69% | 18 | Mar 4, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $33 → $34 | $27.93 | +21.73% | 24 | Mar 4, 2026 | |
| ARGX argenx SE | Maintains: Buy | $915 → $940 | $681.85 | +37.86% | 42 | Feb 27, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $34 | $22.29 | +52.53% | 5 | Feb 26, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $45 → $48 | $17.57 | +173.19% | 28 | Feb 25, 2026 | |
| OTLK Outlook Therapeutics | Reiterates: Neutral | $0.5 | $0.32 | +56.35% | 20 | Feb 18, 2026 | |
| IMVT Immunovant | Reiterates: Buy | $35 | $24.38 | +43.56% | 24 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $13 | $4.68 | +177.78% | 30 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $340 → $1,245 | $294.11 | +323.31% | 31 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $117 | $98.54 | +18.73% | 36 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $22.65 | +67.77% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $5 | $2.40 | +108.33% | 19 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $40 | $27.91 | +43.32% | 3 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.37 | +775.91% | 18 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $2.82 | +467.38% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $27.71 | +66.01% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $2.38 | +194.12% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $59.11 | +99.63% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $34.71 | +133.36% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.64 | +326.83% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $27.62 | +23.10% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.47 | +628.74% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.12 | +32,042.86% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $2.31 | +332.90% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $100.35 | +81.37% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $6.90 | +171.74% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $53.80 | -66.54% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $28.77 | -72.19% | 7 | Jun 11, 2019 |
Minerva Neurosciences
Mar 12, 2026
Maintains: Neutral
Price Target: $4 → $7
Current: $6.55
Upside: +6.87%
Xenon Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $53 → $74
Current: $54.42
Upside: +35.98%
Biohaven
Mar 4, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $8.74
Upside: +14.42%
Theravance Biopharma
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $15
Current: $14.75
Upside: +1.69%
Roivant Sciences
Mar 4, 2026
Maintains: Buy
Price Target: $33 → $34
Current: $27.93
Upside: +21.73%
argenx SE
Feb 27, 2026
Maintains: Buy
Price Target: $915 → $940
Current: $681.85
Upside: +37.86%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $34
Current: $22.29
Upside: +52.53%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $45 → $48
Current: $17.57
Upside: +173.19%
Outlook Therapeutics
Feb 18, 2026
Reiterates: Neutral
Price Target: $0.5
Current: $0.32
Upside: +56.35%
Immunovant
Feb 10, 2026
Reiterates: Buy
Price Target: $35
Current: $24.38
Upside: +43.56%
Feb 3, 2026
Maintains: Buy
Price Target: $20 → $13
Current: $4.68
Upside: +177.78%
Jan 30, 2026
Maintains: Buy
Price Target: $340 → $1,245
Current: $294.11
Upside: +323.31%
Jan 30, 2026
Maintains: Buy
Price Target: $80 → $117
Current: $98.54
Upside: +18.73%
Jan 9, 2026
Reiterates: Buy
Price Target: $38
Current: $22.65
Upside: +67.77%
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $2.40
Upside: +108.33%
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $27.91
Upside: +43.32%
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $1.37
Upside: +775.91%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $2.82
Upside: +467.38%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $27.71
Upside: +66.01%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $2.38
Upside: +194.12%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $59.11
Upside: +99.63%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $34.71
Upside: +133.36%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.64
Upside: +326.83%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $27.62
Upside: +23.10%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $2.47
Upside: +628.74%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $1.12
Upside: +32,042.86%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $2.31
Upside: +332.90%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $100.35
Upside: +81.37%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $6.90
Upside: +171.74%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $53.80
Upside: -66.54%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $28.77
Upside: -72.19%